Background::In light of the significant clinical benefits of antibody-drug conjugates in clinical trials, the human epidermal growth factor receptor 2 (HER2)-low category in breast cancers has gained increasing attention. Therefore, we studied the clinicopathological characteristics of Chinese patients with hormone receptor (HR)-positive/HER2-low early-stage breast cancer and developed a recurrence risk prediction model.Methods::Female patients with HR-positive/HER2-low early-stage breast cancer treated in 29 hospitals of the Chinese Society of Breast Surgery (CSBrS) from Jan 2015 to Dec 2016 were enrolled. Their clinicopathological data and prognostic information were collected, and machine learning methods were used to analyze the prognostic factors.Results::In total, 25,096 patients were diagnosed with breast cancer in 29 hospitals of CSBrS from Jan 2015 to Dec 2016, and clinicopathological data for 6486 patients with HER2-low early-stage breast cancer were collected. Among them, 5629 patients (86.79

作者：Xin Ling；Wu Qian；Zhan Chongming；Qin Hongyan；Xiang Hongyu；Gao Min；Duan Xuening；Liu Yinhua；Ye Jingming；Chinese Society of Breast Surgery (CSBrS)；Chinese Society of Surgery of Chinese Medical Association

来源：中华医学杂志英文版 2023 年 136卷 24期